Evidence map›Paper›PMID 41929232›Full record

ReviewMolecular and clinical oncology2026

Unveiling the mysteries of C1QBP in gynecological tumors (Review).

Hanrui Zhang, Jia Feng, Xidan Zhu, Fuyou Fu, Baolin Li, Tongtong Guo, Jinbo Liu, Ping Zhan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hanrui ZhangDepartment of Gynecology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.
Jia FengDepartment of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Sichuan Province Engineering Technology Research Center of Molecular Diagnosis of Clinical Diseases, Molecular Diagnosis of Clinical Diseases Key Laboratory, Luzhou, Sichuan 646000, P.R. China.
Xidan ZhuDepartment of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Sichuan Province Engineering Technology Research Center of Molecular Diagnosis of Clinical Diseases, Molecular Diagnosis of Clinical Diseases Key Laboratory, Luzhou, Sichuan 646000, P.R. China.
Fuyou FuDepartment of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Sichuan Province Engineering Technology Research Center of Molecular Diagnosis of Clinical Diseases, Molecular Diagnosis of Clinical Diseases Key Laboratory, Luzhou, Sichuan 646000, P.R. China.
Baolin LiDepartment of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Sichuan Province Engineering Technology Research Center of Molecular Diagnosis of Clinical Diseases, Molecular Diagnosis of Clinical Diseases Key Laboratory, Luzhou, Sichuan 646000, P.R. China.
Tongtong GuoDepartment of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Sichuan Province Engineering Technology Research Center of Molecular Diagnosis of Clinical Diseases, Molecular Diagnosis of Clinical Diseases Key Laboratory, Luzhou, Sichuan 646000, P.R. China.
Jinbo LiuDepartment of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Sichuan Province Engineering Technology Research Center of Molecular Diagnosis of Clinical Diseases, Molecular Diagnosis of Clinical Diseases Key Laboratory, Luzhou, Sichuan 646000, P.R. China.
Ping ZhanDepartment of Gynecology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The morbidity and mortality of gynecological tumors have been increasing globally in recent years. The identification of new biomarkers and drug targets has become an opportunity and challenge in the treatment of these tumor types. In recent years, the role of mitochondrial oxidative phosphorylation in the development of gynecological tumors has attracted attention, and existing studies have shown that complement component 1 Q subcomponent-binding protein (C1QBP) is involved in critical biological processes such as proliferation, migration and invasion of these tumors. However, the specific mechanism and function of C1QBP in gynecological tumors remain unknown and further studies are still needed to reveal its role and clinical application prospects. Therefore, the present review describes the changes and mechanism, such as in the apoptosis and invasion of tumor cells, of C1QBP in cervical, ovarian and endometrial cancer. The present review examines the current research progress on C1QBP in gynecological tumors to provide new ideas and methods for diagnosing and treating this disease.

Indexed as

biomarkerscervical cancercomplement component 1 Q subcomponent-binding proteinendometrial cancerovarian cancertherapeutic targets

Identifiers

PMID41929232
PMCPMC13040531

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.